It has been 90 days since we launched the world’s largest global antibacterial public-private partnership to combat antibiotic resistant bacteria. Arguably, we have already started changing the way pre-clinical antibacterial product development is identified, funded, and soon, how it will be managed.
In the first year, $50 million will be committed to research, including $30 million in BARDA funds.
CARB-X Cycles 1 & 2 are now closed.
Register your email below to receive announcements about CARB-X: